Press release
Ovarian Cancer Pipeline Assessment 2024: Therapies, Clinical Trials, Latest FDA, EMA, and PMDA Approvals | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact Therapeutics, Glycotope, ImmunoGen
"Ovarian Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ovarian Cancer Market.
The Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Ovarian Cancer Pipeline Report: https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Ovarian Cancer treatment therapies with a considerable amount of success over the years.
• Ovarian Cancer companies working in the treatment market are Genentech, Genmab, Daiichi Sankyo, Inc, Amgen, Compugen Ltd, NextCure, Sonnet BioTherapeutics, SOTIO Biotech B.V., Akeso, Allarity Therapeutics, Merck Sharp & Dohme, CanariaBio Inc., Allarity Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others, are developing therapies for the Ovarian Cancer treatment
• Emerging Ovarian Cancer therapies in the different phases of clinical trials are- Atezolizumab, Tisotumab Vedotin, DS-6000a, AMG-794, COM701, NC762, SON-1010, SOT101, AK112, 2X-121, Pembrolizumab, Oregovomab, Stenoparib, DP-303c, and others are expected to have a significant impact on the Ovarian Cancer market in the coming years.
• In October 2024, Oncoinvent has administered the first dose to a participant in the Phase II clinical trial of Radspherin, an alpha-radiation therapy, for treating peritoneal carcinomatosis caused by ovarian cancer.
• In September 2024, Theolytics, a UK-based biotechnology company, has secured a £2 million ($2.6 million) grant to fund a Phase I clinical trial for its lead candidate, THEO-260, targeting advanced-stage platinum-resistant ovarian cancer. The non-dilutive funding was awarded by Innovate UK, a division of the UK Government's public body, UK Research and Innovation (UKRI).
• In August 2024, South Korean biopharmaceutical company CanariaBio has completed subject enrollment in the Phase II clinical trial of oregovomab combined with chemotherapy for advanced epithelial ovarian cancer. The trial, named FLORA-6, is a double-blind, placebo-controlled, multicenter study aimed at evaluating oregovomab in conjunction with the chemotherapy drugs paclitaxel and carboplatin as a neoadjuvant treatment for newly diagnosed patients.
Ovarian Cancer Overview
Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and hormones. It typically develops when abnormal cells in the ovaries grow uncontrollably and form tumors. Ovarian cancer is often referred to as a "silent" disease because its symptoms can be vague or go unnoticed until the cancer is advanced. Common symptoms may include bloating, pelvic pain, frequent urination, and difficulty eating. Early detection can be challenging, but with treatment options such as surgery, chemotherapy, and targeted therapies, the prognosis can improve, especially if caught in its early stages.
Get a Free Sample PDF Report to know more about Ovarian Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Ovarian Cancer Drugs Under Different Phases of Clinical Development Include:
• Atezolizumab: Genentech
• Tisotumab Vedotin: Genmab
• DS-6000a: Daiichi Sankyo, Inc
• AMG-794: Amgen
• COM701: Compugen Ltd
• NC762: NextCure
• SON-1010: Sonnet BioTherapeutics
• SOT101: SOTIO Biotech B.V.
• AK112: Akeso
• 2X-121: Allarity Therapeutics
• Pembrolizumab: Merck Sharp & Dohme
• Oregovomab: CanariaBio Inc.
• Stenoparib: Allarity Therapeutics
• DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ovarian Cancer Route of Administration
Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Ovarian Cancer Molecule Type
Ovarian Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Ovarian Cancer Pipeline Therapeutics Assessment
• Ovarian Cancer Assessment by Product Type
• Ovarian Cancer By Stage and Product Type
• Ovarian Cancer Assessment by Route of Administration
• Ovarian Cancer By Stage and Route of Administration
• Ovarian Cancer Assessment by Molecule Type
• Ovarian Cancer by Stage and Molecule Type
DelveInsight's Ovarian Cancer Report covers around 200+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Ovarian Cancer product details are provided in the report. Download the Ovarian Cancer pipeline report to learn more about the emerging Ovarian Cancer therapies
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Ovarian Cancer Therapeutics Market include:
Key companies developing therapies for Ovarian Cancer are - Pfizer, Daiichi Sankyo, Inc., Astellas Pharma Inc, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, ImmunoGen, OncoQuest, Lee's Pharmaceutical, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Bayer, Xennials Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Puma Biotechnology, Inc., MaxCyte, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and others.
Ovarian Cancer Pipeline Analysis:
The Ovarian Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ovarian Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer Treatment.
• Ovarian Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ovarian Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Ovarian Cancer drugs and therapies
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Ovarian Cancer Pipeline Market Drivers
• Increasing prevalence of Ovarian Cancer, increasing research and development activities, launch of novel drugs are some of the important factors that are fueling the Ovarian Cancer Market.
Ovarian Cancer Pipeline Market Barriers
• However, huge expenditure of the treatment methods, adverse effects associated with the drugs and other factors are creating obstacles in the Ovarian Cancer Market growth.
Scope of Ovarian Cancer Pipeline Drug Insight
• Coverage: Global
• Key Ovarian Cancer Companies: Genentech, Genmab, Daiichi Sankyo, Inc, Amgen, Compugen Ltd, NextCure, Sonnet BioTherapeutics, SOTIO Biotech B.V., Akeso, Allarity Therapeutics, Merck Sharp & Dohme, CanariaBio Inc., Allarity Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others
• Key Ovarian Cancer Therapies: Atezolizumab, Tisotumab Vedotin, DS-6000a, AMG-794, COM701, NC762, SON-1010, SOT101, AK112, 2X-121, Pembrolizumab, Oregovomab, Stenoparib, DP-303c, and others
• Ovarian Cancer Therapeutic Assessment: Ovarian Cancer current marketed and Ovarian Cancer emerging therapies
• Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers
Request for Sample PDF Report for Ovarian Cancer Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Ovarian Cancer Report Introduction
2. Ovarian Cancer Executive Summary
3. Ovarian Cancer Overview
4. Ovarian Cancer- Analytical Perspective In-depth Commercial Assessment
5. Ovarian Cancer Pipeline Therapeutics
6. Ovarian Cancer Late Stage Products (Phase II/III)
7. Ovarian Cancer Mid Stage Products (Phase II)
8. Ovarian Cancer Early Stage Products (Phase I)
9. Ovarian Cancer Preclinical Stage Products
10. Ovarian Cancer Therapeutics Assessment
11. Ovarian Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ovarian Cancer Key Companies
14. Ovarian Cancer Key Products
15. Ovarian Cancer Unmet Needs
16 . Ovarian Cancer Market Drivers and Barriers
17. Ovarian Cancer Future Perspectives and Conclusion
18. Ovarian Cancer Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Ovarian Cancer Market https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-20324' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Ovarian Cancer Epidemiology https://www.delveinsight.com/report-store/ovarian-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ovarian Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ovarian Cancer Pipeline Assessment 2024: Therapies, Clinical Trials, Latest FDA, EMA, and PMDA Approvals | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact Therapeutics, Glycotope, ImmunoGen here
News-ID: 3767068 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Ovarian
Ovarian Cancer Diagnostics Market Size: 2033 Statistics
The Ovarian Cancer Diagnostics market is expected to grow from an estimated USD 4814.5 million in 2024 to USD 7795.1 million in 2033, at a CAGR of 5.50%.
The ovarian cancer diagnostics market plays a critical role in the early detection and management of ovarian cancer, one of the most common and lethal gynecological cancers worldwide. Ovarian cancer is often diagnosed at an advanced stage due to the lack of noticeable…
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
